SNPH.Y Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥10.45 |
| 52 Week High | JP¥13.00 |
| 52 Week Low | JP¥8.72 |
| Beta | 0.21 |
| 11 Month Change | -17.08% |
| 3 Month Change | -8.59% |
| 1 Year Change | 17.40% |
| 33 Year Change | -23.62% |
| 5 Year Change | -45.21% |
| Change since IPO | 30.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| SNPH.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.8% | -7.0% | -2.1% |
| 1Y | 17.4% | 8.5% | 29.7% |
Return vs Industry: SNPH.Y exceeded the US Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: SNPH.Y underperformed the US Market which returned 29.6% over the past year.
Price Volatility
| SNPH.Y volatility | |
|---|---|
| SNPH.Y Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SNPH.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SNPH.Y's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,744 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| SNPH.Y fundamental statistics | |
|---|---|
| Market cap | US$3.74b |
| Earnings (TTM) | US$169.34m |
| Revenue (TTM) | US$1.96b |
22.1x
P/E Ratio1.9x
P/S RatioIs SNPH.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNPH.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥302.56b |
| Cost of Revenue | JP¥127.31b |
| Gross Profit | JP¥175.26b |
| Other Expenses | JP¥149.13b |
| Earnings | JP¥26.13b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 75.44 |
| Gross Margin | 57.92% |
| Net Profit Margin | 8.64% |
| Debt/Equity Ratio | 0% |
How did SNPH.Y perform over the long term?
See historical performance and comparison